Using mass-spectrometry—based phosphoproteomics, researchers at the Moffit Cancer Center have identified a mechanism by which BRAF/PTEN-null melanoma cells develop resistance to BRAF inhibitors.
Researchers at the Moffit Cancer Center have identified a mechanism by which BRAF/PTEN-null melanoma cells develop resistance to BRAF inhibitors. Using mass-spectrometry—based phosphoproteomics, the researchers found that treating these mutant-bearing melanoma cells with a BRAF inhibitor was associated with marked changes in fibronectin-based adhesion signaling that were PTEN dependent. These results are a step in the direction of developing combination therapies to prevent resistance and relapse in melanoma patients. Nearly 50% of melanoma patients harbor BRAF mutations and many of these patients relapse on these treatments. Identifying the mechanism of resistance is very important as a prevention strategy.
In their report in Oncogene, the authors present data showing an upregulation of the adhesion molecule fibronectin in a mouse melanoma model, with exposure to a BRAF inhibitor. The authors also conducted a phosphoproteomic analysis of patient tumor samples and identified a similar trend: those treated with a BRAF inhibitor had increased fibronectin expression and signaling, which was PTEN-dependent. Further, induction of fibronectin was associated with reduced overall survival due to a reduced response to the BRAF inhibitor.
The work has significant clinical implications with respect to developing novel combination strategies in melanoma.
Read more at ScienceDaily.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More